Amid a global crisis of cancer, a recent study has shown that nearly 60% of countries don’t even ha…

Medivation turned down that bid a day later, and it's already fielding other offers. Reuters is rep…

Regardless, the analysts think Medivation could fetch at least $66 per share in a sale. That's abou…

India's National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 42 medicines that…

Axovant, incorporated in Switzerland, also benefits from a lower tax rate than Medivation, which wa…

New Delhi, Dec 4 () India's proposal to cap the trade margins available to drug distributors will n…

Beyond cancer immunotherapy, BMS also makes the bloodthinner Eliquis in collaboration with dru…

Boomers will benefit from President Joe Biden's $2,000 cap on prescription drugs for cancer, rheuma…

Merck, which known for its cancer immunotherapy drug Keytruda and its vaccines business, has not be…

Biotech giant Amgen gained FDA approval for its immunotherapy drug targeting leukemia, Blincyto, in…

"Based on these results the company expects to submit a New Drug Application (NDA) for VYXEOS with …

Pfizer had originally invested $25 million in Trillium in September of last year, as part of its br…

To get around that, Sham Mailankody, a medical oncologist and hematologist at Memorial Sloan Ketter…

The device is still in pre-clinical trials, which means it hasn't made its way into humans yet. But…

The San Francisco-based biotech already has one drug on the market to treat prostate cancer with mo…

In April, pharma giant Sanofi went public with a $9.3 billion bid for the company. Medivation had r…

A Proteus-sponsored study of roughly 100 patients with hypertension and type 2 diabetes suggested t…

Dr. Lan Huang, co-founder, CEO, and chair, said she will set a pre-non-disclosure agreement meeting…

Medivation brought one drug to the market, called Xtandi, or enzalutamide, before the acquisition. …